NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

CVS Health has chosen Novo Nordisk's Wegovy as its top obesity treatment, ending coverage for Eli Lilly's Zepbound, impacting around 200,000 patients currently using Zepbound.

Novo Nordisk ended its partnership with Hims & Hers for the weight loss drug Wegovy due to legal non-compliance and safety risks, causing a 5.5% stock drop.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.